Highly purified LSC fraction (CD34+ CD38−) from patient-derived AML xenografts has demonstrated the ability to entirely reconstitute AML tumor heterogeneity and disease in mouse models [4]. This evidence concerns the gene CD38 and acute myeloid leukemia.